2019 Future of Metachromatic Leukodystrophy (MLD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 40 pages | ID: 28DF2A346F5EN
VPAResearch

Abstracts

The global demand for Metachromatic Leukodystrophy (MLD) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Metachromatic Leukodystrophy (MLD) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Metachromatic Leukodystrophy (MLD) pipeline companies from advancing their products into Phase 3 or Phase 4.

Metachromatic Leukodystrophy (MLD) Report Description-

The 2019 pipeline study on Metachromatic Leukodystrophy (MLD) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Metachromatic Leukodystrophy (MLD) pipeline compounds.

The Metachromatic Leukodystrophy (MLD) pipeline guide presents information on all active drugs currently being developed for Metachromatic Leukodystrophy (MLD). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Metachromatic Leukodystrophy (MLD) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Metachromatic Leukodystrophy (MLD) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Metachromatic Leukodystrophy (MLD) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Metachromatic Leukodystrophy (MLD) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Metachromatic Leukodystrophy (MLD) pipeline report includes-

• An overview of Metachromatic Leukodystrophy (MLD) disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Metachromatic Leukodystrophy (MLD) pipeline
• Company wise list of Metachromatic Leukodystrophy (MLD) pipeline
• Mechanism of Action wise Metachromatic Leukodystrophy (MLD) pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Metachromatic Leukodystrophy (MLD) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Metachromatic Leukodystrophy (MLD) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Metachromatic Leukodystrophy (MLD) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Metachromatic Leukodystrophy (MLD) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Metachromatic Leukodystrophy (MLD) pipeline, H1- 2019
3.5 Mechanism of Action wise Metachromatic Leukodystrophy (MLD) Pipeline Candidates

4 ARMAGEN INC METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE DETAILS

4.1 ArmaGen Inc Business Profile
4.2 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 HOMOLOGY MEDICINES INC METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE DETAILS

5.1 Homology Medicines Inc Business Profile
5.2 Homology Medicines Inc Metachromatic Leukodystrophy (MLD) Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 MAGENTA THERAPEUTICS INC METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE DETAILS

6.1 Magenta Therapeutics Inc Business Profile
6.2 Magenta Therapeutics Inc Metachromatic Leukodystrophy (MLD) Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 ORCHARD THERAPEUTICS LTD METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE DETAILS

7.1 Orchard Therapeutics Ltd Business Profile
7.2 Orchard Therapeutics Ltd Metachromatic Leukodystrophy (MLD) Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 RECURSION PHARMACEUTICALS INC METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE DETAILS

8.1 Recursion Pharmaceuticals Inc Business Profile
8.2 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 REGENXBIO INC METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE DETAILS

9.1 RegenxBio Inc Business Profile
9.2 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 TAKEDA PHARMACEUTICAL COMPANY LTD METACHROMATIC LEUKODYSTROPHY (MLD) PIPELINE DETAILS

10.1 Takeda Pharmaceutical Company Ltd Business Profile
10.2 Takeda Pharmaceutical Company Ltd Metachromatic Leukodystrophy (MLD) Drug Details
10.3 Drug Snapshot
  10.3.1 Originator
  10.3.2 Collaborator/Co-Developer
  10.3.3 Route of Administration
  10.3.4 Orphan Drug/Fast Track/Special Designation
  10.3.5 Geography
  10.3.6 Type of Molecular Entity
  10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. LATEST METACHROMATIC LEUKODYSTROPHY (MLD) DRUG PIPELINE DEVELOPMENTS, 2019

12. APPENDIX

12.1 About Us
12.2 Sources and Methodology
12.3 Contact Information